Pharmaceutical companies including Novartis and Roche have teamed up with global cancer organizations in an alliance aimed at getting more oncology medications to poorer countries.
Reuters HealthNovartis temporarily suspended the production of the company’s Lutathera and Pluvicto cancer therapies at facilities in Italy and New Jersey after potential quality issues were discovered in their manufacturing.
ReutersGlaxoSmithKline said on April 6 the company’s consumer arm stopped shipments of supplements and vitamins to Russia as a result of Moscow’s invasion of Ukraine and would prioritize the supply of over-the-counter medicines for basic needs.
The World Health Organization said on April 5 it will supply thousands of doses of life-saving antiretroviral drugs to Ukraine to cover the needs of HIV patients in the country for the next 12 months.
On the heels of the Point of Care Marketing Association’s 2022 Industry Summit and in partnership with leading medical market research company MedSurvey, Havas Media Group (HMG) revealed findings from a new research study examining the matrix of influence surrounding prescribing drugs for patients. The findings identify who beyond MDs exerts influence over prescribing decisions, as well as the concerns, behaviors, trigger moments, and media habits of these influencers.
Sanofi said the French healthcare group priced a first sustainability-linked bond issue that will be indexed on access to medicines, and worth 1.5 billion euros ($1.7 billion).
U.S. drugmaker Eli Lilly said on March 15 the company would continue to supply drugs for urgent medical conditions such as cancer and diabetes to Russia, but will suspend all investments and no longer start new clinical studies in the country.
Alzheimer’s patient groups, disappointed by Medicare’s plan to sharply limit coverage of new drugs for the brain-wasting disease, are planning publicity and lobbying campaigns to protest a proposal they say could delay their use for 10 years.
The U.S. Food and Drug Administration placed a clinical hold on Gilead Sciences’ use of injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV and HIV pre-exposure prophylaxis (PrEP).
Merck on Oct. 25 revealed positive results from two Phase III trials on a potential treatment for adults with HIV-1 infection and are virologically suppressed on different antiretroviral regimens (ART).
